Of a total 35 glioma patients, the estimated Kaplan-Meier survival with IDH1 wild type (IDH1 WT) was 13 months (range 11.25 to 14.75 months), while patients with IDH1 R132H mutation (IDH1 R132H) was 29 months (range 11.8 to 46.2 months). This evidence concerns the gene IDH1 and glioma.